Basilea Pharmaceutica AG: Basileas Partner Asahi Kasei Pharma reicht Antrag auf Marktzulassung (NDA) von Isavuconazol in Japan ein : vimarsana.com

Ad hoc-Mitteilung gemäss Art. 53 KR Basel, 30. September 2021 Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass ihr Partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma) in Japan

Related Keywords

Germany , Norway , Australia , Iceland , United States , Liechtenstein , Canada , Russia , Switzerland , Turkey , America , German , Swiss , Basilea , Her Corporation , Services Or Achievements Of Basilea , S Partnership , Swiss Exchange , Market Approval , Hoc Notification , Fungal Infections , Milestone Payment , For Approval , Sales Markets , Tee Payment , Percent Range , Product Sales , End June , Prior Year Period , About Isavuconazole , Member States , Active Ingredient Orphan Drug Status , Latin America , Asia Pacific Space , Near East , North Africa , About Basilea , Cancer Or Infections , Drug Candidates , Areas Oncology , Infectious Diseases , Ticker Symbol , Website Basilea , Exclusion Clause This Message , Her Business Activities , Product Candidate , Such Propositional , Factors Of Uncertainty , Services Or Achievements , New Information , Source Instructions , Restricted Access , Admission Status , Notes Press Release , Harmaceutica , Asileas , Artner , Sahi , Asei , Harma , Eicht , Ntrag , Arktzulassung , Savuconazol , Apan ,